Spero Therapeutics, Inc. (SPRO)

NASDAQ: SPRO · Real-Time Price · USD

1.190

-0.005 (-0.42%)

At close: Jul 29, 2026, 4:00 PM EDT

1.229

+0.039 (3.29%)

After-hours: Jul 29, 2026, 7:57 PM EDT

Spero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	56.13	40.27	52.89	76.33	109.11	112.58
Short-Term Investments	-	-	-	-	-	33.82
Cash & Short-Term Investments	56.13	40.27	52.89	76.33	109.11	146.4
Cash Growth	14.81%	-23.87%	-30.71%	-30.04%	-25.47%	15.36%
Accounts Receivable	-	25.36	49.39	95.74	-	-
Other Receivables	0.04	0.03	3.09	1.55	1.08	2.64
Total Trade Receivables	0.04	25.39	52.48	97.29	1.08	2.64
Other Current Assets	1.44	1.63	1.91	4.18	3.38	8.83
Total Current Assets	57.61	67.29	107.28	131.21	113.57	157.87
Net Property, Plant & Equipment	1.26	1.48	3.11	4.16	5.49	7.56
Other Long-Term Assets	0.15	0.15	0.15	0.44	5.74	5.64
Total Assets	59.02	68.92	110.54	182.39	124.8	171.07

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	0.22	0.69	7.31	1.38	0.62	1.1
Accrued Expenses	3.14	5.58	17.72	6.56	8.97	14.35
Current Portion of Leases	1.97	1.96	1.75	1.72	1.69	1.36
Unearned Revenue	-	0.26	22.12	27.11	10.37	1.86
Other Current Liabilities	0.16	0.38	0.17	0.39	-	-
Total Current Liabilities	5.49	8.87	49.07	37.15	21.65	18.67
Long-Term Debt	-	-	-	-	-	48.41
Long-Term Leases	0.51	0.94	2.55	3.83	4.96	5.97
Other Long-Term Liabilities	0.09	0.09	12.8	34.52	22.26	9.73
Total Long-Term Liabilities	0.6	1.03	15.35	38.34	27.22	64.11
Total Liabilities	6.09	9.9	64.42	75.5	48.87	82.78

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Preferred Stock	-	-	-	-	-	0
Common Stock	0.06	0.06	0.06	0.05	0.05	0.03
Additional Paid-in Capital	511.15	510.03	505.71	497.91	489.76	455.72
Accumulated Other Comprehensive Income	-	-	-	-	-	-0
Retained Earnings	-458.27	-451.07	-459.64	-391.07	-413.88	-367.46
Shareholders' Equity	52.93	59.02	46.12	106.89	75.93	88.29
Total Liabilities & Equity	59.02	68.92	110.54	182.39	124.8	171.07

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2.47	2.9	4.3	5.54	6.65	55.75
Net Cash (Debt)	53.66	37.37	48.59	70.79	102.46	90.65
Net Cash Growth	19.43%	-23.09%	-31.36%	-30.91%	13.02%	-23.86%
Net Cash Per Share	0.94	0.63	0.90	1.34	2.73	2.93
Book Value	52.93	59.02	46.12	106.89	75.93	88.29
Book Value Per Share	0.92	1.00	0.85	2.02	2.02	2.86
Tangible Book Value	52.93	59.02	46.12	106.89	75.93	88.29
Tangible Book Value Per Share	0.92	1.00	0.85	2.02	2.02	2.86

SEC Filings: 10-K · 10-Q